Long‐term health economic evaluation of automated insulin delivery system compared with continuous subcutaneous insulin infusion pumps and CGM in a real‐world setting in Finnish paediatric and adult individuals with type 1 diabetes
Open Access
- 27 June 2025
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (9) , 4793-4801
Abstract
Aims: The use of automated insulin delivery (AID) systems is associated with improved glycaemic control in individuals with type 1 diabetes (T1DM). However, AID systems are more expensive than other treatment modalities for T1DM. The aim of this study was to evaluate the long‐term cost‐effectiveness of AID compared to continuous subcutaneous insulin infusion (CSII) combined with continuous glucose monitoring (CGM) in individuals with T1DM at Kuopio University Hospital, Finland. Materials and Methods: The study included 336 individuals (mean age: 26.7 years, SD: 15.9 years), with a mean duration of diabetes of 16.6 years. Outcomes were projected in the base case of 50 years using the IQVIA CORE Diabetes Model (v10.0). Clinical data were sourced from electronic health records (EHRs), including changes in glycated haemoglobin (HbA1c) and events of hypoglycaemia and ketoacidosis. Costs were expressed in 2023 Euros (EUR). Results: The AID system was associated with an improvement in quality‐adjusted life expectancy of 2.3 quality‐adjusted life‐years (QALYs) compared to CSII plus CGM. These benefits came from the delayed and reduced incidence of diabetes‐related complications. The mean HbA1c improvement was 12.1 ± 11.7 mmol/mol (3.3% ± 3.2%) in the AID group. Direct costs were estimated to be 26 076 EUR higher for AID than for CSII plus CGM, and AID was associated with an incremental cost‐effectiveness ratio (ICER) of 11 184 EUR per QALY gained. Conclusions: Based on the results of this first cost‐effectiveness study conducted in Finland, a willingness‐to‐pay (WTP) threshold of 50 000 EUR per QALY gained suggests that AID is more cost‐effective than CSII plus CGM for the treatment of T1DM in a real‐world setting.Keywords
This publication has 35 references indexed in Scilit:
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesNew England Journal of Medicine, 2019
- Conversion of Hypoglycemia Utility Decrements from Categorical Units Reflecting Event History into Event Specific Disutility Scores Applicable to Diabetes Decision ModelsValue in Health, 2018
- Glycemic Control and Excess Mortality in Type 1 DiabetesNew England Journal of Medicine, 2014
- Validation of the IMS CORE Diabetes ModelValue in Health, 2014
- Review of Utility Values for Economic Modeling in Type 2 DiabetesValue in Health, 2014
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005
- Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 dataHealth Economics, 2004
- Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic NephropathyJAMA, 2003
- The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)Diabetologia, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993